Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NBIB-0000223 · NBIB-223

Other · developed by Neurocrine Biosciences

Phase 1 Most advanced trial
NBIX Developer
1 Registered trials

What is NBIB-0000223?

NBIB-0000223 (also called NBIB-223) is a drug studied in Friedreich's ataxia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NBIB-223
Drug type
Other
Therapy area
Neurology
Developer
Neurocrine Biosciences (NBIX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07934303 Phase 1 Friedreich's Ataxia Not yet recruiting NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Friedreich's Ataxia

More from Neurocrine Biosciences

Follow NBIX, the company behind NBIB-0000223

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.